TY  - JOUR
AU  - Miloradović, Zoran
AU  - Mihailović-Stanojević, Nevena
AU  - Grujić-Milanović, Jelica
AU  - Ivanov, Milan
AU  - Jerkić, Mirjana
AU  - Jovović, Đurđica
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/373
AB  - Nitric oxide (NO) has been suggested to play a pivotal role in ischemic acute renal failure (ARF) but there are controversies about its role in hypertensive and non hypertensive ischemic kidney. Multiple strategies including administration of exogenous NO donors have been shown to protect the kidney against toxic or ischemic injury, suggesting endothelial dysfunction as impaired NO generation due to ischemia. However, in postischemic kidney, NO derived from inducible nitric oxide synthase (iNOS) has been considered to enhance the tissue damage while iNOS inhibition decreased the tubular damage. It is well known decrease in basal production of NO in essential hypertension and that long lasting hypertension damages medium size and small-size blood vessels, therefore predisposes nephroangiosclerosis patients to ARF. Many studies have shown that long term stimulation of NO release in normotension improves renal haemodymnamics and kidney function in ischemic form of ARF. On the other hand, there are studies that have shown that NO synthesis stimulation has no effect or even worsens tubular damage in postischemic hypertensive kidney. Therefore, it seems likely that NO supplementation plays different role in postischemic renal damage development, beneficial in well preserved normotensive kidney and limited in postischemic hypertensive kidney due to disturbed tubuloglomerular response, vasoreactivity and kidney vascular structure.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Pharmaceutical Biotechnology
T1  - Nitric Oxide Supplementation in Postischemic Acute Renal Failure: Normotension Versus Hypertension
EP  - 1367
IS  - 9
SP  - 1364
VL  - 12
DO  - 10.2174/138920111798281153
ER  - 

@article{
author = "Miloradović, Zoran and Mihailović-Stanojević, Nevena and Grujić-Milanović, Jelica and Ivanov, Milan and Jerkić, Mirjana and Jovović, Đurđica",
year = "2011",
abstract = "Nitric oxide (NO) has been suggested to play a pivotal role in ischemic acute renal failure (ARF) but there are controversies about its role in hypertensive and non hypertensive ischemic kidney. Multiple strategies including administration of exogenous NO donors have been shown to protect the kidney against toxic or ischemic injury, suggesting endothelial dysfunction as impaired NO generation due to ischemia. However, in postischemic kidney, NO derived from inducible nitric oxide synthase (iNOS) has been considered to enhance the tissue damage while iNOS inhibition decreased the tubular damage. It is well known decrease in basal production of NO in essential hypertension and that long lasting hypertension damages medium size and small-size blood vessels, therefore predisposes nephroangiosclerosis patients to ARF. Many studies have shown that long term stimulation of NO release in normotension improves renal haemodymnamics and kidney function in ischemic form of ARF. On the other hand, there are studies that have shown that NO synthesis stimulation has no effect or even worsens tubular damage in postischemic hypertensive kidney. Therefore, it seems likely that NO supplementation plays different role in postischemic renal damage development, beneficial in well preserved normotensive kidney and limited in postischemic hypertensive kidney due to disturbed tubuloglomerular response, vasoreactivity and kidney vascular structure.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Pharmaceutical Biotechnology",
title = "Nitric Oxide Supplementation in Postischemic Acute Renal Failure: Normotension Versus Hypertension",
pages = "1367-1364",
number = "9",
volume = "12",
doi = "10.2174/138920111798281153"
}

Miloradović, Z., Mihailović-Stanojević, N., Grujić-Milanović, J., Ivanov, M., Jerkić, M.,& Jovović, Đ.. (2011). Nitric Oxide Supplementation in Postischemic Acute Renal Failure: Normotension Versus Hypertension. in Current Pharmaceutical Biotechnology
Bentham Science Publ Ltd, Sharjah., 12(9), 1364-1367.
https://doi.org/10.2174/138920111798281153

Miloradović Z, Mihailović-Stanojević N, Grujić-Milanović J, Ivanov M, Jerkić M, Jovović Đ. Nitric Oxide Supplementation in Postischemic Acute Renal Failure: Normotension Versus Hypertension. in Current Pharmaceutical Biotechnology. 2011;12(9):1364-1367.
doi:10.2174/138920111798281153 .

Miloradović, Zoran, Mihailović-Stanojević, Nevena, Grujić-Milanović, Jelica, Ivanov, Milan, Jerkić, Mirjana, Jovović, Đurđica, "Nitric Oxide Supplementation in Postischemic Acute Renal Failure: Normotension Versus Hypertension" in Current Pharmaceutical Biotechnology, 12, no. 9 (2011):1364-1367,
https://doi.org/10.2174/138920111798281153 . .

TY  - JOUR
AU  - Ivanov, Milan
AU  - Mihailović-Stanojević, Nevena
AU  - Grujić-Milanović, Jelica
AU  - Jovović, D.
AU  - Miloradović, Zoran
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/344
AB  - Patients with pre-existing hypertension are at a particular risk of fatal outcome due to acute renal failure (ARF). We investigate the effects of angiotensin II type-1 receptor blocker (ARB) losartan, on haemodynamics and biochemical parameters in adult male spontaneously hypertensive rats (SHR) with ischemia/reperfusion ARF. SHR were randomly selected in three experimental groups: sham-operated group (SHAM), ARF group, and ARF+LOS group (losartan, 10 mg/kg/b.w. given by infusion during the period of three hours after reperfusion). Beside the improvement of systemic haemodynamics 24 h after reperfusion, losartan significantly increased renal blood flow (RBF: 19.33 +/- 3.29 ml/min/kg vs. 8.03 +/- 1.04 ml/min/kg, p  lt  0.05) and decreased renal vascular resistance (RVR) compared to ARF (8.85 +/- 1.21 mmHg x min x kg/ml vs. 19.90 +/- 2.35 mmHg x min x kg/ml, p  lt  0.001). Plasma creatinine (Pcr), urea (Pu) and phosphates (Pphos) were significantly reduced in ARF+LOS group compared to ARF group (Pcr: 99.11 +/- 14.56 mu mol/l vs. 242.71 +/- 20.25 mu mol/l, p  lt  0.001; Pu: 33.72 +/- 4.69 mmol/l vs. 61.90 +/- 3.93 mmol/l, p  lt  0.001; 2.7 +/- 0.42 mmol/l vs. 5.57 +/- 0.61 mmol/l, p  lt  0.01). Our results demonstrate that losartan improves systemic and regional haemodynamic and biochemical parameters in hypertension with ARF.
PB  - Akademiai Kiado Zrt, Budapest
T2  - Acta Physiologica Hungarica
T1  - Prevention of systemic and regional haemodynamic alterations, hypercreatininemia, hyperuremia and hyperphosphatemia by losartan in hypertension with acute renal failure
EP  - 7
IS  - 1
SP  - 1
VL  - 98
DO  - 10.1556/APhysiol.98.2011.1.1
ER  - 

@article{
author = "Ivanov, Milan and Mihailović-Stanojević, Nevena and Grujić-Milanović, Jelica and Jovović, D. and Miloradović, Zoran",
year = "2011",
abstract = "Patients with pre-existing hypertension are at a particular risk of fatal outcome due to acute renal failure (ARF). We investigate the effects of angiotensin II type-1 receptor blocker (ARB) losartan, on haemodynamics and biochemical parameters in adult male spontaneously hypertensive rats (SHR) with ischemia/reperfusion ARF. SHR were randomly selected in three experimental groups: sham-operated group (SHAM), ARF group, and ARF+LOS group (losartan, 10 mg/kg/b.w. given by infusion during the period of three hours after reperfusion). Beside the improvement of systemic haemodynamics 24 h after reperfusion, losartan significantly increased renal blood flow (RBF: 19.33 +/- 3.29 ml/min/kg vs. 8.03 +/- 1.04 ml/min/kg, p  lt  0.05) and decreased renal vascular resistance (RVR) compared to ARF (8.85 +/- 1.21 mmHg x min x kg/ml vs. 19.90 +/- 2.35 mmHg x min x kg/ml, p  lt  0.001). Plasma creatinine (Pcr), urea (Pu) and phosphates (Pphos) were significantly reduced in ARF+LOS group compared to ARF group (Pcr: 99.11 +/- 14.56 mu mol/l vs. 242.71 +/- 20.25 mu mol/l, p  lt  0.001; Pu: 33.72 +/- 4.69 mmol/l vs. 61.90 +/- 3.93 mmol/l, p  lt  0.001; 2.7 +/- 0.42 mmol/l vs. 5.57 +/- 0.61 mmol/l, p  lt  0.01). Our results demonstrate that losartan improves systemic and regional haemodynamic and biochemical parameters in hypertension with ARF.",
publisher = "Akademiai Kiado Zrt, Budapest",
journal = "Acta Physiologica Hungarica",
title = "Prevention of systemic and regional haemodynamic alterations, hypercreatininemia, hyperuremia and hyperphosphatemia by losartan in hypertension with acute renal failure",
pages = "7-1",
number = "1",
volume = "98",
doi = "10.1556/APhysiol.98.2011.1.1"
}

Ivanov, M., Mihailović-Stanojević, N., Grujić-Milanović, J., Jovović, D.,& Miloradović, Z.. (2011). Prevention of systemic and regional haemodynamic alterations, hypercreatininemia, hyperuremia and hyperphosphatemia by losartan in hypertension with acute renal failure. in Acta Physiologica Hungarica
Akademiai Kiado Zrt, Budapest., 98(1), 1-7.
https://doi.org/10.1556/APhysiol.98.2011.1.1

Ivanov M, Mihailović-Stanojević N, Grujić-Milanović J, Jovović D, Miloradović Z. Prevention of systemic and regional haemodynamic alterations, hypercreatininemia, hyperuremia and hyperphosphatemia by losartan in hypertension with acute renal failure. in Acta Physiologica Hungarica. 2011;98(1):1-7.
doi:10.1556/APhysiol.98.2011.1.1 .

Ivanov, Milan, Mihailović-Stanojević, Nevena, Grujić-Milanović, Jelica, Jovović, D., Miloradović, Zoran, "Prevention of systemic and regional haemodynamic alterations, hypercreatininemia, hyperuremia and hyperphosphatemia by losartan in hypertension with acute renal failure" in Acta Physiologica Hungarica, 98, no. 1 (2011):1-7,
https://doi.org/10.1556/APhysiol.98.2011.1.1 . .

TY  - JOUR
AU  - Mihailović-Stanojević, Nevena
AU  - Jovović, Đurđica
AU  - Miloradović, Zoran
AU  - Grujić-Milanović, Jelica
AU  - Jerkić, Mirjana
AU  - Marković-Lipkovski, Jasmina
PY  - 2009
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/216
AB  - Background. The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy. Methods. Six-month-old female SHR were randomly selected in six groups. Two control groups (SH(6), SH(12)) received vehicle. Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w. i.v.) twice in a 3-week interval. Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR. Animals were killed after 6 or 12 weeks, respectively. Haemodynamic measurements were performed on anaesthetized animals, blood and urine samples were taken for biochemical analysis and the left kidney was processed for morphological studies. Results. Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria. Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR. Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy. Conclusion. Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
PB  - Oxford Univ Press, Oxford
T2  - Nephrology Dialysis Transplantation
T1  - Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan
EP  - 1150
IS  - 4
SP  - 1142
VL  - 24
DO  - 10.1093/ndt/gfn596
ER  - 

@article{
author = "Mihailović-Stanojević, Nevena and Jovović, Đurđica and Miloradović, Zoran and Grujić-Milanović, Jelica and Jerkić, Mirjana and Marković-Lipkovski, Jasmina",
year = "2009",
abstract = "Background. The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy. Methods. Six-month-old female SHR were randomly selected in six groups. Two control groups (SH(6), SH(12)) received vehicle. Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w. i.v.) twice in a 3-week interval. Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR. Animals were killed after 6 or 12 weeks, respectively. Haemodynamic measurements were performed on anaesthetized animals, blood and urine samples were taken for biochemical analysis and the left kidney was processed for morphological studies. Results. Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria. Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR. Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy. Conclusion. Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.",
publisher = "Oxford Univ Press, Oxford",
journal = "Nephrology Dialysis Transplantation",
title = "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan",
pages = "1150-1142",
number = "4",
volume = "24",
doi = "10.1093/ndt/gfn596"
}

Mihailović-Stanojević, N., Jovović, Đ., Miloradović, Z., Grujić-Milanović, J., Jerkić, M.,& Marković-Lipkovski, J.. (2009). Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan. in Nephrology Dialysis Transplantation
Oxford Univ Press, Oxford., 24(4), 1142-1150.
https://doi.org/10.1093/ndt/gfn596

Mihailović-Stanojević N, Jovović Đ, Miloradović Z, Grujić-Milanović J, Jerkić M, Marković-Lipkovski J. Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan. in Nephrology Dialysis Transplantation. 2009;24(4):1142-1150.
doi:10.1093/ndt/gfn596 .

Mihailović-Stanojević, Nevena, Jovović, Đurđica, Miloradović, Zoran, Grujić-Milanović, Jelica, Jerkić, Mirjana, Marković-Lipkovski, Jasmina, "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan" in Nephrology Dialysis Transplantation, 24, no. 4 (2009):1142-1150,
https://doi.org/10.1093/ndt/gfn596 . .

TY  - JOUR
AU  - Mihailović-Stanojević, Nevena
AU  - Miloradović, Zoran
AU  - Grujić-Milanović, Jelica
AU  - Ivanov, Milan
AU  - Jovović, Đurđica
PY  - 2009
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/217
AB  - Ageing and hypertension are the major risk factors for the development of cardiovascular and renal diseases, and the renin-angiotensin system has been shown responsible for these pathologies. Thus, the aim of this study was to compare the effects of losartan, angiotensin II type-1 receptor blocker, on systolic (SBP), diastolic (DBP), and mean (MBP) blood pressure, pulse pressure (PP) and heart rate as well as regional haemodynamics, cardiac hypertrophy and biochemical parameters in adult (L(9): 9-month-old) and aged (L(18): 18-month-old) spontaneously hypertensive rats (SHRs). Aged match untreated SHRs served as controls (U(9): 9-month-old and U(18): 18-month-old). Aortal blood flow and resistance were significantly improved by losartan treatment in L(9) vs. U(9) (p  lt  0.05). In aged SHRs, losartan significantly reduced SBP, MBP, PP, right ventricle weight index, and improved age-related impairment of left ventricular weight index (U(18): 4.21 +/- 0.09 mg/g vs. U(9): 3.54 +/- 0.34 mg/g, p  lt  0.05 and vs. L(18): 3.65 +/- 0.07 mg/g, p  lt  0.001), carotid, renal, and aortal vascular resistance, and glomerular filtration rate (U(18): 2.75 +/- 0.27 ml/min/kg vs. U(9): 4.84 +/- 0.85 ml/min/kg, p  lt  0.05 and vs. L(18): 3.65 +/- 0.07 ml/min/kg, p  lt  0.05). These results demonstrate significantly impaired systemic and regional haemodynamics and left ventricular hypertrophy in old SHRs. Losartan decreased age and hypertension associated cardiovascular risk by decreasing vascular resistance and pressure overload, ventricular hypertrophy, and preserving kidney function.
PB  - General Physiol And Biophysics, Bratislava
T2  - General Physiology & Biophysics
T1  - Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats
EP  - 118
SP  - 112
VL  - 28
UR  - https://hdl.handle.net/21.15107/rcub_rimi_217
ER  - 

@article{
author = "Mihailović-Stanojević, Nevena and Miloradović, Zoran and Grujić-Milanović, Jelica and Ivanov, Milan and Jovović, Đurđica",
year = "2009",
abstract = "Ageing and hypertension are the major risk factors for the development of cardiovascular and renal diseases, and the renin-angiotensin system has been shown responsible for these pathologies. Thus, the aim of this study was to compare the effects of losartan, angiotensin II type-1 receptor blocker, on systolic (SBP), diastolic (DBP), and mean (MBP) blood pressure, pulse pressure (PP) and heart rate as well as regional haemodynamics, cardiac hypertrophy and biochemical parameters in adult (L(9): 9-month-old) and aged (L(18): 18-month-old) spontaneously hypertensive rats (SHRs). Aged match untreated SHRs served as controls (U(9): 9-month-old and U(18): 18-month-old). Aortal blood flow and resistance were significantly improved by losartan treatment in L(9) vs. U(9) (p  lt  0.05). In aged SHRs, losartan significantly reduced SBP, MBP, PP, right ventricle weight index, and improved age-related impairment of left ventricular weight index (U(18): 4.21 +/- 0.09 mg/g vs. U(9): 3.54 +/- 0.34 mg/g, p  lt  0.05 and vs. L(18): 3.65 +/- 0.07 mg/g, p  lt  0.001), carotid, renal, and aortal vascular resistance, and glomerular filtration rate (U(18): 2.75 +/- 0.27 ml/min/kg vs. U(9): 4.84 +/- 0.85 ml/min/kg, p  lt  0.05 and vs. L(18): 3.65 +/- 0.07 ml/min/kg, p  lt  0.05). These results demonstrate significantly impaired systemic and regional haemodynamics and left ventricular hypertrophy in old SHRs. Losartan decreased age and hypertension associated cardiovascular risk by decreasing vascular resistance and pressure overload, ventricular hypertrophy, and preserving kidney function.",
publisher = "General Physiol And Biophysics, Bratislava",
journal = "General Physiology & Biophysics",
title = "Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats",
pages = "118-112",
volume = "28",
url = "https://hdl.handle.net/21.15107/rcub_rimi_217"
}

Mihailović-Stanojević, N., Miloradović, Z., Grujić-Milanović, J., Ivanov, M.,& Jovović, Đ.. (2009). Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats. in General Physiology & Biophysics
General Physiol And Biophysics, Bratislava., 28, 112-118.
https://hdl.handle.net/21.15107/rcub_rimi_217

Mihailović-Stanojević N, Miloradović Z, Grujić-Milanović J, Ivanov M, Jovović Đ. Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats. in General Physiology & Biophysics. 2009;28:112-118.
https://hdl.handle.net/21.15107/rcub_rimi_217 .

Mihailović-Stanojević, Nevena, Miloradović, Zoran, Grujić-Milanović, Jelica, Ivanov, Milan, Jovović, Đurđica, "Effects of angiotensin II type-1 receptor blocker losartan on age-related cardiovascular risk in spontaneously hypertensive rats" in General Physiology & Biophysics, 28 (2009):112-118,
https://hdl.handle.net/21.15107/rcub_rimi_217 .

TY  - JOUR
AU  - Miloradović, Zoran
AU  - Mihailović-Stanojević, Nevena
AU  - Grujić-Milanović, Jelica
AU  - Ivanov, Milan
AU  - Kuburović, Gordana
AU  - Marković-Lipkovski, Jasmina
AU  - Jovović, Đurđica
PY  - 2009
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/230
AB  - Postischemic acute renal failure is worsened when occurs in a various conditions with impaired nitric oxide (NO) synthesis, such as arterial hypertension. Reoxygenation itself increases ischemic injury through the massive production of oxygen-free radicals. Therefore, we have directed our investigations to effects of both NO donor and antioxidant treatment on course of acute renal failure in experimental hypertension. Experiments were performed in anesthetized, adult male spontaneously hypertensive rats. In ARF groups the right kidney was removed, and rats were subjected to renal ischemia by clamping the left renal artery for 40 min. Experimental group received NO donor L-arginine (2 g/kg b.m.) (L-Arg group), or oxidant scavenger vitamin C (100 mg/kg b.m.) (Vit C group) during 3 days before the period of ischaemia. All parameters were measured 24 h after reperfusion. The mean arterial pressure was markedly reduced and renal vascular resistance significantly dropped in the ARF+L-Arg group vs. ARF group. Tubular injuries were similar between the ARF+L-Arg and ARF groups. Intensity of tubular necrosis and dilatation was markedly reduced in ARF+Vit C group in comparison to ARE L-arginine failed to reduce tubular injury, despite its evident improvement of systemic and renal haemodynainic, thus NO seems to act as a double-egged sword, but reduction of tubular injury promotes vitamin C as an effective chemoprotectant against ishemia-reperfusion tubular injury in hypertension.
PB  - General Physiol And Biophysics, Bratislava
T2  - General Physiology & Biophysics
T1  - Comparative effects of L-arginine and vitamin C pretreatment in SHR with induced postischemic acute renal failure
EP  - 111
SP  - 105
VL  - 28
UR  - https://hdl.handle.net/21.15107/rcub_rimi_230
ER  - 

@article{
author = "Miloradović, Zoran and Mihailović-Stanojević, Nevena and Grujić-Milanović, Jelica and Ivanov, Milan and Kuburović, Gordana and Marković-Lipkovski, Jasmina and Jovović, Đurđica",
year = "2009",
abstract = "Postischemic acute renal failure is worsened when occurs in a various conditions with impaired nitric oxide (NO) synthesis, such as arterial hypertension. Reoxygenation itself increases ischemic injury through the massive production of oxygen-free radicals. Therefore, we have directed our investigations to effects of both NO donor and antioxidant treatment on course of acute renal failure in experimental hypertension. Experiments were performed in anesthetized, adult male spontaneously hypertensive rats. In ARF groups the right kidney was removed, and rats were subjected to renal ischemia by clamping the left renal artery for 40 min. Experimental group received NO donor L-arginine (2 g/kg b.m.) (L-Arg group), or oxidant scavenger vitamin C (100 mg/kg b.m.) (Vit C group) during 3 days before the period of ischaemia. All parameters were measured 24 h after reperfusion. The mean arterial pressure was markedly reduced and renal vascular resistance significantly dropped in the ARF+L-Arg group vs. ARF group. Tubular injuries were similar between the ARF+L-Arg and ARF groups. Intensity of tubular necrosis and dilatation was markedly reduced in ARF+Vit C group in comparison to ARE L-arginine failed to reduce tubular injury, despite its evident improvement of systemic and renal haemodynainic, thus NO seems to act as a double-egged sword, but reduction of tubular injury promotes vitamin C as an effective chemoprotectant against ishemia-reperfusion tubular injury in hypertension.",
publisher = "General Physiol And Biophysics, Bratislava",
journal = "General Physiology & Biophysics",
title = "Comparative effects of L-arginine and vitamin C pretreatment in SHR with induced postischemic acute renal failure",
pages = "111-105",
volume = "28",
url = "https://hdl.handle.net/21.15107/rcub_rimi_230"
}

Miloradović, Z., Mihailović-Stanojević, N., Grujić-Milanović, J., Ivanov, M., Kuburović, G., Marković-Lipkovski, J.,& Jovović, Đ.. (2009). Comparative effects of L-arginine and vitamin C pretreatment in SHR with induced postischemic acute renal failure. in General Physiology & Biophysics
General Physiol And Biophysics, Bratislava., 28, 105-111.
https://hdl.handle.net/21.15107/rcub_rimi_230

Miloradović Z, Mihailović-Stanojević N, Grujić-Milanović J, Ivanov M, Kuburović G, Marković-Lipkovski J, Jovović Đ. Comparative effects of L-arginine and vitamin C pretreatment in SHR with induced postischemic acute renal failure. in General Physiology & Biophysics. 2009;28:105-111.
https://hdl.handle.net/21.15107/rcub_rimi_230 .

Miloradović, Zoran, Mihailović-Stanojević, Nevena, Grujić-Milanović, Jelica, Ivanov, Milan, Kuburović, Gordana, Marković-Lipkovski, Jasmina, Jovović, Đurđica, "Comparative effects of L-arginine and vitamin C pretreatment in SHR with induced postischemic acute renal failure" in General Physiology & Biophysics, 28 (2009):105-111,
https://hdl.handle.net/21.15107/rcub_rimi_230 .

TY  - JOUR
AU  - Jovanović, Dijana
AU  - Jovović, Đurđica
AU  - Mihailović-Stanojević, Nevena
AU  - Miloradović, Zoran
AU  - Naumović, Radomir
AU  - Dimitrijević, Jovan
AU  - Maksić, Nebojša
AU  - Đukanović, Ljubica
PY  - 2009
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/238
AB  - Recent studies indicated pulse pressure as a risk factor for left ventricular hypertrophy, myocardial infarction, congestive heart failure and stroke as well as chronic renal failure progression. The present study examined the effects of carvedilol and its combination with captopril on blood pressure, left ventricular hypertrophy, kidney vascular changes and kidney function in spontaneously hypertensive rats with adriamycin nephropathy. Four groups of 20 SHR each were involved: (1) control group: SHR; (2) ADR group: SHR treated with ADR (2 mg/kg i.v. twice in 20 days); (3) ADR-C group: SHR treated with ADR and carvedilol (30 mg/kg/day) and (4) ADR-CC group: SHR treated with ADR and carvedilol (30 mg/kg/day) and captopril (60 mg/kg/day). Systolic-, diastolic- and mean-pressures and pulse pressure were determined at weeks 6 and 12 after the second ADR injection; and body weight, creatinine clearance and proteinuria at weeks -3, 6 and 12. The rats were sacrificed at week 6 or 12, the weights of the left and right ventricles and kidneys measured and the kidney vascular index was calculated as described by Bader and Mayer. Both carvedilol alone and combined with captopril significantly reduced systemic blood pressure but the effect of the latter was more pronounced and registered from week 4 till the end of the study. Carvedilol and its combination with captopril significantly decreased SBP, DBP and MAP. They also decreased PP, prevented the development of LVH, and renal vascular changes and slowed the progression of chronic renal failure and these effects were stronger in the ADR-CC group than in the ADR-C group. The antihypertensive drugs failed to prevent proteinuria in ADR SHR. Significant positive correlations were found between PP (but not SBP, DBP and MAP) and both proteinuria and Ccr in all groups of rats. In conclusion, carvedilol alone, but more strongly in combination with captopril, significantly reduced blood pressure, PP, LVH, renal blood vessel changes and chronic renal failure progression.
PB  - Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux
T2  - Biomedicine & Pharmacotherapy
T1  - Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy
EP  - 576
IS  - 8
SP  - 571
VL  - 63
DO  - 10.1016/j.biopha.2008.10.006
ER  - 

@article{
author = "Jovanović, Dijana and Jovović, Đurđica and Mihailović-Stanojević, Nevena and Miloradović, Zoran and Naumović, Radomir and Dimitrijević, Jovan and Maksić, Nebojša and Đukanović, Ljubica",
year = "2009",
abstract = "Recent studies indicated pulse pressure as a risk factor for left ventricular hypertrophy, myocardial infarction, congestive heart failure and stroke as well as chronic renal failure progression. The present study examined the effects of carvedilol and its combination with captopril on blood pressure, left ventricular hypertrophy, kidney vascular changes and kidney function in spontaneously hypertensive rats with adriamycin nephropathy. Four groups of 20 SHR each were involved: (1) control group: SHR; (2) ADR group: SHR treated with ADR (2 mg/kg i.v. twice in 20 days); (3) ADR-C group: SHR treated with ADR and carvedilol (30 mg/kg/day) and (4) ADR-CC group: SHR treated with ADR and carvedilol (30 mg/kg/day) and captopril (60 mg/kg/day). Systolic-, diastolic- and mean-pressures and pulse pressure were determined at weeks 6 and 12 after the second ADR injection; and body weight, creatinine clearance and proteinuria at weeks -3, 6 and 12. The rats were sacrificed at week 6 or 12, the weights of the left and right ventricles and kidneys measured and the kidney vascular index was calculated as described by Bader and Mayer. Both carvedilol alone and combined with captopril significantly reduced systemic blood pressure but the effect of the latter was more pronounced and registered from week 4 till the end of the study. Carvedilol and its combination with captopril significantly decreased SBP, DBP and MAP. They also decreased PP, prevented the development of LVH, and renal vascular changes and slowed the progression of chronic renal failure and these effects were stronger in the ADR-CC group than in the ADR-C group. The antihypertensive drugs failed to prevent proteinuria in ADR SHR. Significant positive correlations were found between PP (but not SBP, DBP and MAP) and both proteinuria and Ccr in all groups of rats. In conclusion, carvedilol alone, but more strongly in combination with captopril, significantly reduced blood pressure, PP, LVH, renal blood vessel changes and chronic renal failure progression.",
publisher = "Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux",
journal = "Biomedicine & Pharmacotherapy",
title = "Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy",
pages = "576-571",
number = "8",
volume = "63",
doi = "10.1016/j.biopha.2008.10.006"
}

Jovanović, D., Jovović, Đ., Mihailović-Stanojević, N., Miloradović, Z., Naumović, R., Dimitrijević, J., Maksić, N.,& Đukanović, L.. (2009). Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy. in Biomedicine & Pharmacotherapy
Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux., 63(8), 571-576.
https://doi.org/10.1016/j.biopha.2008.10.006

Jovanović D, Jovović Đ, Mihailović-Stanojević N, Miloradović Z, Naumović R, Dimitrijević J, Maksić N, Đukanović L. Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy. in Biomedicine & Pharmacotherapy. 2009;63(8):571-576.
doi:10.1016/j.biopha.2008.10.006 .

Jovanović, Dijana, Jovović, Đurđica, Mihailović-Stanojević, Nevena, Miloradović, Zoran, Naumović, Radomir, Dimitrijević, Jovan, Maksić, Nebojša, Đukanović, Ljubica, "Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy" in Biomedicine & Pharmacotherapy, 63, no. 8 (2009):571-576,
https://doi.org/10.1016/j.biopha.2008.10.006 . .

TY  - JOUR
AU  - Miloradović, Zoran
AU  - Jerkić, Mirjana
AU  - Jovović, Đurđica
AU  - Mihailović-Stanojević, Nevena
AU  - Grujić-Milanović, Jelica
AU  - Stošić, Gordana
AU  - Marković-Lipkovski, Jasmina
PY  - 2007
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/162
AB  - Background. Acute renal failure (ARF) is a devastating illness, especially when it occurs in various conditions with impaired nitric oxide (NO) synthesis, such as arterial hypertension, heart failure and some renal diseases. We have directed our investigations to effects of both angiotensin II (AII) and endothelin (ET) receptor blockade associated with mild or strong NO deficiency on haemodynamic, biochemical and morphological parameters in experimental post-ischaemic ARF. Methods. In this study, we used bosentan (dual, ETA/ETB-receptor antagonist), losartan (non-peptide, competitive antagonist of type I AII receptor), and NG-nitro-L-arginine methyl ester (L-NAME), inhibitor of NO synthesis. Experiments were performed in anaesthetized, adult male Wistar rats. The right kidney was removed and the renal ischaemia was performed by clamping the left renal artery for 45 min. Experimental groups received receptor antagonists (bosentan or losartan) or vehicle (saline) in the femoral vein 20 min before, during and 20 min after the period of ischaemia. L-NAME was given as i.v. bolus before each antagonist infusion. All parameters were measured 24 h after reperfusion. Results. Our results showed that strong NO blockade overcame effects of both ET and AII receptor blockade in experimental post-ischaemic ARF. In addition, the AII receptor blockade had a harmful effect on this condition, probably due to disturbed autoregulatory renal function. On the other hand, ET and AII receptor blockade in mild NO blockade associated with reperfusion injury, improves the most haemodynamic, biochemical and morphological parameters. Conclusions. We concluded that experimental post-ischaemic ARF is neither AII nor ET mediated in case of strong NO blockade, but, in more realistic conditions of mild NO deficiency, these peptides represent significant players whose receptor blockade expressed relevant therapeutic potential.
PB  - Oxford Univ Press, Oxford
T2  - Nephrology Dialysis Transplantation
T1  - Bosentan and losartan ameliorate acute renal failure associated with mild but not strong NO blockade
EP  - 2484
IS  - 9
SP  - 2476
VL  - 22
DO  - 10.1093/ndt/gfm213
ER  - 

@article{
author = "Miloradović, Zoran and Jerkić, Mirjana and Jovović, Đurđica and Mihailović-Stanojević, Nevena and Grujić-Milanović, Jelica and Stošić, Gordana and Marković-Lipkovski, Jasmina",
year = "2007",
abstract = "Background. Acute renal failure (ARF) is a devastating illness, especially when it occurs in various conditions with impaired nitric oxide (NO) synthesis, such as arterial hypertension, heart failure and some renal diseases. We have directed our investigations to effects of both angiotensin II (AII) and endothelin (ET) receptor blockade associated with mild or strong NO deficiency on haemodynamic, biochemical and morphological parameters in experimental post-ischaemic ARF. Methods. In this study, we used bosentan (dual, ETA/ETB-receptor antagonist), losartan (non-peptide, competitive antagonist of type I AII receptor), and NG-nitro-L-arginine methyl ester (L-NAME), inhibitor of NO synthesis. Experiments were performed in anaesthetized, adult male Wistar rats. The right kidney was removed and the renal ischaemia was performed by clamping the left renal artery for 45 min. Experimental groups received receptor antagonists (bosentan or losartan) or vehicle (saline) in the femoral vein 20 min before, during and 20 min after the period of ischaemia. L-NAME was given as i.v. bolus before each antagonist infusion. All parameters were measured 24 h after reperfusion. Results. Our results showed that strong NO blockade overcame effects of both ET and AII receptor blockade in experimental post-ischaemic ARF. In addition, the AII receptor blockade had a harmful effect on this condition, probably due to disturbed autoregulatory renal function. On the other hand, ET and AII receptor blockade in mild NO blockade associated with reperfusion injury, improves the most haemodynamic, biochemical and morphological parameters. Conclusions. We concluded that experimental post-ischaemic ARF is neither AII nor ET mediated in case of strong NO blockade, but, in more realistic conditions of mild NO deficiency, these peptides represent significant players whose receptor blockade expressed relevant therapeutic potential.",
publisher = "Oxford Univ Press, Oxford",
journal = "Nephrology Dialysis Transplantation",
title = "Bosentan and losartan ameliorate acute renal failure associated with mild but not strong NO blockade",
pages = "2484-2476",
number = "9",
volume = "22",
doi = "10.1093/ndt/gfm213"
}

Miloradović, Z., Jerkić, M., Jovović, Đ., Mihailović-Stanojević, N., Grujić-Milanović, J., Stošić, G.,& Marković-Lipkovski, J.. (2007). Bosentan and losartan ameliorate acute renal failure associated with mild but not strong NO blockade. in Nephrology Dialysis Transplantation
Oxford Univ Press, Oxford., 22(9), 2476-2484.
https://doi.org/10.1093/ndt/gfm213

Miloradović Z, Jerkić M, Jovović Đ, Mihailović-Stanojević N, Grujić-Milanović J, Stošić G, Marković-Lipkovski J. Bosentan and losartan ameliorate acute renal failure associated with mild but not strong NO blockade. in Nephrology Dialysis Transplantation. 2007;22(9):2476-2484.
doi:10.1093/ndt/gfm213 .

Miloradović, Zoran, Jerkić, Mirjana, Jovović, Đurđica, Mihailović-Stanojević, Nevena, Grujić-Milanović, Jelica, Stošić, Gordana, Marković-Lipkovski, Jasmina, "Bosentan and losartan ameliorate acute renal failure associated with mild but not strong NO blockade" in Nephrology Dialysis Transplantation, 22, no. 9 (2007):2476-2484,
https://doi.org/10.1093/ndt/gfm213 . .